Resource Library

ResourceLibrary

Porter, 4 years old

Taking YUVIWEL as part of a clinical trial since age 2.

Others are not actual patients.

Thinking about YUVIWEL?

Caregiver Brochure

Learn about treatment with YUVIWEL and the support available along the way

A•S•A•P Brochure

Explore patient support options throughout treatment with YUVIWEL

What to Expect Brochure

Discover what to expect when starting treatment with YUVIWEL

Understanding Coverage: A Guide for Caregivers

Learn about the insurance process and what to expect through the YUVIWEL prescription journey

Already prescribed YUVIWEL?

How to Give YUVIWEL

Detailed instructions on how to prepare and give YUVIWEL to your child

Letter of Medical Necessity for Travel

If traveling by plane, ask your healthcare provider to sign this letter before getting to the airport

Travel Checklist

Use this checklist to help you get ready for your trip

A·S·A·P Consent Form

Fill out this online form to consent to enroll in A•S•A•P

A.S.A.P SMS icon

Get a text when it’s time to give YUVIWEL

The A·S·A·P Text Messaging Service is designed to help you and your child stay on track when taking YUVIWEL.

Connect with a PAL and register for updates

A Patient Access Liaison (PAL) can provide you with individualized support and education about achondroplasia and treatment with YUVIWEL. Fill out the form below to receive important information about YUVIWEL and connect with a PAL.

*Required field.

Connect With a PAL

By checking this box, I confirm that I would like an Ascendis Patient Access Liaison to contact me with information about achondroplasia. I understand the PAL is not providing me medical advice and is not part of my healthcare team. I further certify that I am a resident of the United States and 18 years or older.

A PAL will reach out to you via phone.

Marketing Communications

By checking this box, I am agreeing to receive marketing communications from Ascendis Pharma and its service providers or partners, such as newsletters and updates, and to allow them to contact me for my opinion regarding products, programs, and services.

I understand that at any time I may unsubscribe by clicking on the designated link in the material.

Privacy Consent, Privacy Notice, and Terms of Use

By checking this box, I give my consent to the collection and processing of the personal and/or sensitive information requested above for the purposes I selected above. I understand that the information will be handled in accordance with the Ascendis Pharma Privacy Policy and Terms of Use. I understand that I may withdraw my consent at any time by contacting Ascendis at DataPrivacy@ascendispharma.com.

What is YUVIWEL?
YUVIWEL is a prescription medicine used to increase linear growth in children 2 years and older with achondroplasia with open growth plates (epiphyses).

YUVIWEL is approved under accelerated approval based on an improvement in annualized growth velocity. Continued approval may be contingent upon verification and description of clinical benefit in confirmatory trials.

USE AND IMPORTANT SAFETY INFORMATION

IMPORTANT SAFETY INFORMATION

What are the possible side effects of YUVIWEL?
YUVIWEL may cause serious side effects, including risk of low blood pressure. If your child experiences a decrease in blood pressure or symptoms of low blood pressure (dizziness, feeling tired, and/or nausea) while being treated with YUVIWEL, call your child’s healthcare provider.

The most common side effects of YUVIWEL include injection site

What is YUVIWEL?
YUVIWEL is a prescription medicine used to increase linear growth in children 2 years and older with achondroplasia with open growth plates (epiphyses).

YUVIWEL is approved under accelerated approval based on an improvement in annualized growth velocity. Continued approval may be contingent upon verification and description of clinical benefit in confirmatory trials.

USE AND IMPORTANT SAFETY INFORMATION

What is YUVIWEL?
YUVIWEL is a prescription medicine used to increase linear growth in children 2 years and older with achondroplasia with open growth plates (epiphyses).

YUVIWEL is approved under accelerated approval based on an improvement in annualized growth velocity. Continued approval may be contingent upon verification and description of clinical benefit in confirmatory trials.

IMPORTANT SAFETY INFORMATION

What are the possible side effects of YUVIWEL?

YUVIWEL may cause serious side effects, including risk of low blood pressure. If your child experiences a decrease in blood pressure or symptoms of low blood pressure (dizziness, feeling tired, and/or nausea) while being treated with YUVIWEL, call your child’s healthcare provider.

The most common side effects of YUVIWEL include injection site reactions (redness, itching, skin discoloration, bleeding, swelling, bruising, pain, and blistering).

Before you give YUVIWEL to your child, tell the healthcare provider about all of your child’s medical conditions, including if they:

  • have kidney problems
  • are pregnant or plan to become pregnant. It is not known if YUVIWEL will harm the unborn baby
  • are breastfeeding or plan to breastfeed. It is not known if YUVIWEL passes into breast milk

Tell the healthcare provider about all the medicines your child takes, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

These are not all of the possible side effects of YUVIWEL. Call your doctor for medical advice about side effects. You are encouraged to report side effects to FDA at 1-800-FDA-1088 or at www.fda.gov/medwatch. You may also report side effects to Ascendis Pharma at 1-844-442-7236.

Please see the full Prescribing Information and Patient Information for YUVIWEL.

A•S•A•P=Ascendis Signature Access Program.